1039356-98-3 Usage
Description
Imidazo[1,5-a]pyridine-1-carboxylic acid, Methyl ester is a chemical compound characterized by an imidazo[1,5-a]pyridine ring fused with a carboxylic acid group and a methyl ester substituent. It is recognized for its potential as a versatile intermediate in pharmaceutical synthesis and for its therapeutic properties, which include anti-cancer, anti-inflammatory, and anti-bacterial activities. IMidazo[1,5-a]pyridine-1-carboxylic acid, Methyl ester also holds promise in organic synthesis and as a building block for developing novel biologically active compounds.
Uses
Used in Pharmaceutical Industry:
Imidazo[1,5-a]pyridine-1-carboxylic acid, Methyl ester serves as a crucial intermediate in the synthesis of a variety of drugs and pharmaceuticals, leveraging its structural features to contribute to the development of new medicinal agents.
Used in Organic Synthesis:
IMidazo[1,5-a]pyridine-1-carboxylic acid, Methyl ester is utilized in organic synthesis as a building block, enabling the creation of novel compounds with potential biological activity, thereby expanding the scope of chemical research and drug discovery.
Used in Therapeutic Applications:
Imidazo[1,5-a]pyridine-1-carboxylic acid, Methyl ester is studied for its potential therapeutic uses, particularly in anti-cancer treatments, where it may contribute to inhibiting tumor growth and progression. Additionally, its anti-inflammatory and anti-bacterial properties suggest possible applications in treating inflammatory conditions and combating bacterial infections, respectively.
Check Digit Verification of cas no
The CAS Registry Mumber 1039356-98-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,9,3,5 and 6 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1039356-98:
(9*1)+(8*0)+(7*3)+(6*9)+(5*3)+(4*5)+(3*6)+(2*9)+(1*8)=163
163 % 10 = 3
So 1039356-98-3 is a valid CAS Registry Number.
1039356-98-3Relevant articles and documents
Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy
Trotter, B. Wesley,Nanda, Kausik K.,Burgey, Christopher S.,Potteiger, Craig M.,Deng, James Z.,Green, Ahren I.,Hartnett, John C.,Kett, Nathan R.,Wu, Zhicai,Henze, Darrell A.,Penna, Kimberly Della,Desai, Reshma,Leitl, Michael D.,Lemaire, Wei,White, Rebecca B.,Yeh, Suzie,Urban, Mark O.,Kane, Stefanie A.,Hartman, George D.,Bilodeau, Mark T.
scheme or table, p. 2354 - 2358 (2011/06/17)
A new series of imidazopyridine CB2 agonists is described. Structural optimization improved CB2/CB1 selectivity in this series and conferred physical properties that facilitated high in vivo exposure, both centrally and peripherally. Administration of a h
